Concepedia

A.B. Siegel

AS

8

Publications

300

Citations

8

H-Index

2006

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

National Taiwan University Hospital

University of California, Los Angeles

Massachusetts General Hospital

Kindai University

A.B. Siegel is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in oncology, radiation oncology, and medicine.

ORCID

Top concepts

Publications per year

2006–2020

8

Publications

8

S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma

Anthony B. El-Khoueiry, Cathryn Rankin, A.B. Siegel et al. · British Journal of Cancer · 2014 · 121 citations · Full text

A phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results

Josep M. Llovet, Karen Shepard, RS Finn et al. · Annals of Oncology · 2019 · 67 citations · Full text

, , +9

Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein

Jonathan D. Schwartz, M. Schwartz, Deborah Lehrer et al. · Journal of Clinical Oncology · 2006 · 56 citations

, , +21

1017TiP KEYNOTE-937 trial in progress: adjuvant pembrolizumab in patients with hepatocellular carcinoma (HCC) and complete radiologic response after surgical resection or local ablation

Arndt Vogel, Andrew X. Zhu, Ann‐Lii Cheng et al. · Annals of Oncology · 2020 · 13 citations

, , +10

Prevalence of high‐risk human papilloma virus among women with hepatitis C virus before liver transplantation

P Tarallo, Janice Smolowitz, Damaris Carriero et al. · Transplant Infectious Disease · 2013 · 11 citations · Full text

Rows per page

1–5 of 8